Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | BHMT | Q93088 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19088336 | 0.83 | MVD (0.41) | MVDBHMTSLC6A9MEN1KMT2A | |
| SCHEMBL25477299 | 0.81 | MAOA (0.32) | MAOAMAOB | |
| SCHEMBL16158922 | 0.79 | MVD (0.42) | MVDBHMTSLC6A9LTA4H | |
| SCHEMBL13427909 | 0.79 | MAOA (0.36) | MAOAMAOBCA14 | |
| SCHEMBL6536011 | 0.79 | MAOA (0.36) | MAOAMAOBCA14 | |
| SCHEMBL1455947 | 0.78 | ALDH1A1 (0.40) | MEN1KMT2ALTA4H | |
| SCHEMBL3293560 | 0.78 | MAOA (0.36) | MAOAMAOBCA14CTSK | |
| SCHEMBL1404486 | 0.78 | MEN1 (0.49) | MVDMAOAMAOBCA14CTSK | |
| SCHEMBL30511042 | 0.78 | FPR3 (0.38) | MAOAMAOBCA14CTSK | |
| SCHEMBL6535041 | 0.77 | MAOA (0.44) | MAOAMAOBCA14CTSKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757609-B1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8022047-B2 | Combination anticancer agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| CN-101291675-B | Novel anticancer concomitant drug | CHUGAI PHARMACEUTICAL CO LTD | 2011-04-13 | — | — | CN | disclosed |
| US-7910593-B2 | Water-soluble prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20090149478-A1 | NOVEL COMBINATION ANTICANCER AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2009-06-11 | — | — | US | disclosed |
| US-20090118271-A1 | Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-05-07 | — | — | US | disclosed |
| CN-101291675-A | Novel anticancer concomitant drug | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-10-22 | — | — | CN | disclosed |
| EP-1938823-A1 | AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1925309-A1 | NOVEL ANTICANCER CONCOMITANT DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1757609-A1 | NOVEL WATER-SOLUBLE PRODRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149478-A1 | NOVEL COMBINATION ANTICANCER AGENTS | KRAS, TOP1, ERBB3 | MVD 3572/4885MAOA 1148/4885MAOB 1300/4885 |
| US-20080015157-A1 | Novel Water-Soluble Prodrugs | ADH1A, ADH1C, SLC43A1 | MVD 4073/4885MAOA 3137/4885MAOB 1867/4885 |
| US-20090118271-A1 | Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug | TP53, SLC10A1, BRCA1 | MVD 4832/4885MAOA 3745/4885MAOB 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.